NVCR News and Press, NovoCure Limited From 05/24/21

SHANGHAI and SAN FRANCISCO, May 24, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced treatment of the first patient in Greater China in the METIS trial, a Phase 3 pivotal trial being conducted by Z...

Novocure (NVCR) announces that the U.S. FDA has approved the company’s Investigational Device Exemption ((IDE)) supplement, reducing the enrollment requirement for its LUNAR trial to 276 non-small cell lung cancer ((NSCLC)) patients with a 12 months follow-up.Shares up nearly ...

IDE supplement incorporates recommended changes from the interim analysis of the LUNAR trial conducted by an independent data monitoring committee Novocure (NASDAQ: NVCR) today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Investigat...

When you're hunting for stocks that could juice your portfolio with quadruple-digit percent increases, there's (at least) one big choice to make. Is it a better bet to go with an established business that's doing what nobody else can do in a way that's paying off more and more over time, or...

Medical device company Novocure 's (NASDAQ: NVCR) shareholders have been cheering the company's recent success in its phase 3 clinical trial as the stock responded on the good news from an independent data monitoring company's positive findings. On a Fool Live episode recorded...

Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q1 2021 Earnings Call Apr 29, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q1 2021 Earnings Call Transcript

NovoCure Limited (NVCR) Q1 2021 Earnings Conference Call April 29, 2021, 08:00 AM ET Company Participants Adam Daney - Investor Relations William Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Ashley Cordova - Chief Financial Officer Uri Weinberg - Chief Science Officer Pr...

Novocure (NVCR) shares are down 4.9% in premarket trading after the company delivered disappointing Q1 results.Novocure missed on both revenues and EPS.The company had a net loss of $4.1M in the quarter compared to net income of $4M in the prior-year period.Revenue of $134.7M, howev...

The following slide deck was published by NovoCure Limited in conjunction with their 2021 Q1 earnings call. For further details see: NovoCure Limited 2021 Q1 - Results - Earnings Call Presentation

NovoCure (NVCR): Q1 GAAP EPS of -$0.04 misses by $0.06.Revenue of $134.7M (+32.3% Y/Y) misses by $3.41M.There were 3,454 active patients at March 31, 2021, representing 12% growth compared to March 31, 2020, and 1% growth compared to December 31, 2020.Press Release For further details see: ...